{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:43:12Z","timestamp":1791474192210,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,27]]},"DOI":"10.7759\/cureus.51196","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T05:05:17Z","timestamp":1703739917000},"source":"Crossref","is-referenced-by-count":3,"title":["Transepidermal Water Loss and T-helper 2 (Th2)-Associated Inflammatory Markers in Two Pediatric Patients During the First Four Weeks of Treatment With the Oral Janus Kinase Inhibitor Upadacitinib"],"prefix":"10.7759","author":[{"given":"Kenta","family":"Horimukai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.002","article-title":"Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies","volume":"66","author":"Furue M","year":"2017","unstructured":"Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, Kadono T. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017, 66:398-403. 10.1016\/j.alit.2016.12.002","journal-title":"Allergol Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12778","article-title":"The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis","volume":"170","author":"Danby SG","year":"2014","unstructured":"Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014, 170:914-21. 10.1111\/bjd.12778","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2006.06.002","article-title":"Thymus and activation regulated chemokine (TARC)\/CCL17 and skin diseases","volume":"43","author":"Saeki H","year":"2006","unstructured":"Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)\/CCL17 and skin diseases. J Dermatol Sci. 2006, 43:75-84. 10.1016\/j.jdermsci.2006.06.002","journal-title":"J Dermatol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2011.011065","article-title":"The usefulness of combined measurements of squamous cell carcinoma antigens 1 and 2 in diagnosing atopic dermatitis","volume":"49","author":"Ohta S","year":"2012","unstructured":"Ohta S, Shibata R, Nakao Y, et al.. The usefulness of combined measurements of squamous cell carcinoma antigens 1 and 2 in diagnosing atopic dermatitis. Ann Clin Biochem. 2012, 49:277-84. 10.1258\/acb.2011.011065","journal-title":"Ann Clin Biochem"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity","volume":"71","author":"Landheer J","year":"2014","unstructured":"Landheer J, de Bruin-Weller M, Boonacker C, Hijnen D, Bruijnzeel-Koomen C, R\u00f6ckmann H. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. J Am Acad Dermatol. 2014, 71:1160-6. 10.1016\/j.jaad.2014.07.031","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2017.06.016","article-title":"Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients","volume":"67","author":"Okawa T","year":"2018","unstructured":"Okawa T, Yamaguchi Y, Kou K, et al.. Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients. Allergol Int. 2018, 67:124-30. 10.1016\/j.alit.2017.06.016","journal-title":"Allergol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.07.005","article-title":"Serum squamous cell carcinoma antigen (SCCA)-2 correlates with clinical severity of pediatric atopic dermatitis in Ishigaki cohort","volume":"95","author":"Takeuchi S","year":"2019","unstructured":"Takeuchi S, Furusyo N, Ono J, et al.. Serum squamous cell carcinoma antigen (SCCA)-2 correlates with clinical severity of pediatric atopic dermatitis in Ishigaki cohort. J Dermatol Sci. 2019, 95:70-5. 10.1016\/j.jdermsci.2019.07.005","journal-title":"J Dermatol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19081","article-title":"The impact of dupilumab on skin barrier function: a systematic review","volume":"37","author":"Montero-Vilchez T","year":"2023","unstructured":"Montero-Vilchez T, Sanabria-de-la-Torre R, Sanchez-Diaz M, Ure\u00f1a-Paniego C, Molina-Leyva A, Arias-Santiago S. The impact of dupilumab on skin barrier function: a systematic review. J Eur Acad Dermatol Venereol. 2023, 37:1284-92. 10.1111\/jdv.19081","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima C","year":"2022","unstructured":"Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022, 71:40-6. 10.1016\/j.alit.2021.10.004","journal-title":"Allergol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt A","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al.. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021, 157:1047-55. 10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan H","year":"2022","unstructured":"Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022, 35:e15636. 10.1111\/dth.15636","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.073","article-title":"Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis","volume":"56","author":"Krejci-Manwaring J","year":"2007","unstructured":"Krejci-Manwaring J, Tusa MG, Carroll C, et al.. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007, 56:211-6. 10.1016\/j.jaad.2006.05.073","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1401211","article-title":"A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis","volume":"29","author":"Liu L","year":"2018","unstructured":"Liu L, Ong G. A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. J Dermatolog Treat. 2018, 29:501-9. 10.1080\/09546634.2017.1401211","journal-title":"J Dermatolog Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/all.14664","article-title":"Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis","volume":"76","author":"Rohner MH","year":"2021","unstructured":"Rohner MH, Thormann K, Cazzaniga S, Yousefi S, Simon HU, Schlapbach C, Simon D. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy. 2021, 76:1268-70. 10.1111\/all.14664","journal-title":"Allergy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16549","article-title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"49","author":"Hagino T","year":"2022","unstructured":"Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022, 49:1158-67. 10.1111\/1346-8138.16549","journal-title":"J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa H","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020, 82:823-31. 10.1016\/j.jaad.2019.12.015","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13719","article-title":"Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab","volume":"62","author":"Mizuno M","year":"2021","unstructured":"Mizuno M, Horiguchi G, Teramukai S, et al.. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Australas J Dermatol. 2021, 62:e504-9. 10.1111\/ajd.13719","journal-title":"Australas J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/srt.12037","article-title":"International guidelines for the in vivo assessment of skin properties in non-clinical settings: Part 2. transepidermal water loss and skin hydration","volume":"19","author":"du Plessis J","year":"2013","unstructured":"du Plessis J, Stefaniak A, Eloff F, et al.. International guidelines for the in vivo assessment of skin properties in non-clinical settings: Part 2. transepidermal water loss and skin hydration. Skin Res Technol. 2013, 19:265-78. 10.1111\/srt.12037","journal-title":"Skin Res Technol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0176","article-title":"Stratum corneum hydration as a potential marker of response to dupilumab in atopic dermatitis: a prospective observational study","author":"Montero-Vilchez T","year":"2023","unstructured":"Montero-Vilchez T, Rodriguez-Pozo JA, Cuenca-Barrales C, Sanabria-de-la-Torre R, Torres-de-Pinedo JM, Arias-Santiago S. Stratum corneum hydration as a potential marker of response to dupilumab in atopic dermatitis: a prospective observational study. Dermatitis. 2023, 10.1089\/derm.2023.0176","journal-title":"Dermatitis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204706-transepidermal-water-loss-and-t-helper-2-th2-associated-inflammatory-markers-in-two-pediatric-patients-during-the-first-four-weeks-of-treatment-with-the-oral-janus-kinase-inhibitor-upadacitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:58Z","timestamp":1707509518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204706-transepidermal-water-loss-and-t-helper-2-th2-associated-inflammatory-markers-in-two-pediatric-patients-during-the-first-four-weeks-of-treatment-with-the-oral-janus-kinase-inhibitor-upadacitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.51196","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}